Woensdag 24 juni 2015, AMSTERDAM (Dow Jones)–Kiadis Pharma nv (KDS.AE) maakt woensdag bekend dat het orderboek voor de geplande beursgang van het biofarmaceutische concern uit Amsterdam gevuld is. In totaal is ingetekend op 2.272.727 aandelen, aldus Kiadis in een persbericht. Dit aantal kan eventueel met maximaal 15% worden uitgebreid tot 2,61 miljoen stuks. Daarnaast is… Continue reading Orderboek beursgang Kiadis Pharma gevuld
Blog posts
BioMarin Submits Drisapersen MAA to EMA for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
SAN RAFAEL, Calif., June 8, 2015 (GLOBE NEWSWIRE) — BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for drisapersen, an investigational antisense oligonucleotide drug candidate for the treatment of the largest subset of Duchenne muscular dystrophy (DMD) amenable to single exon skipping. DMD… Continue reading BioMarin Submits Drisapersen MAA to EMA for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Kiadis Pharma announces intention to launch an initial public offering on Euronext Amsterdam and Euronext Brussels
Amsterdam, The Netherlands, June 3, 2015 – Kiadis Pharma B.V. (“Kiadis Pharma”, “Kiadis” or “the Company”), a clinical stage biopharmaceutical company developing innovative cellbased immunotherapy treatments, announces today its intention to raise new funds through an Initial Public Offering and listing of the entire share capital of a newly incorporated holding company on Euronext Amsterdam… Continue reading Kiadis Pharma announces intention to launch an initial public offering on Euronext Amsterdam and Euronext Brussels
EMA grants Kiadis Pharma’s Lead Product ATIR™ ATMP Certificate for Quality and Non-clinical Data
Amsterdam, The Netherlands, May 13, 2015 – Kiadis Pharma B.V. (“Kiadis Pharma” or “the Company”), a clinical stage biopharmaceutical company developing innovative immunotherapy treatments, today announces that its lead product ATIR™ for blood cancers has been granted an Advanced Therapy Medicinal Product (ATMP) certificate for manufacturing quality and non-clinical data by the European Medicines Agency… Continue reading EMA grants Kiadis Pharma’s Lead Product ATIR™ ATMP Certificate for Quality and Non-clinical Data
Kiadis Pharma Appoints Dr. Vincent Brichard to its Supervisory Board
Amsterdam, The Netherlands, May 7, 2015 – Kiadis Pharma B.V. (“Kiadis Pharma” or “the Company”), a clinical stage biopharmaceutical company developing innovative immunotherapy treatments, today announces the appointment of Dr. Vincent Brichard as an independent member of its Supervisory Board. Dr. Brichard has more than 25 years’ experience in the oncology and immunology field, including… Continue reading Kiadis Pharma Appoints Dr. Vincent Brichard to its Supervisory Board
